Rapport Therapeutics Inc.
RAPP
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.18B
Close$
$0.88
98.1% downside
Current Fair Value
98.1% downsideOvervalued by 98.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.18 Billion |
|---|---|
| Enterprise Value | $2.12 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.86 |
| Beta | 0.95 |
| Outstanding Shares | 47,473,174 |
Return
| Return on Equity | -32.43% |
|---|---|
| Return on Assets | -29.88% |
| Return on Invested Capital | -35.39% |
Valuation & Multiples
| P/E Ratio | -14.96 |
|---|---|
| PEG | -13.39 |
| Price to Sales | - |
| Price to Book Ratio | 5.92 |
| Enterprise Value to Revenue | 106.11 |
| Enterprise Value to EBIT | -13.93 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.96
Average shareholder expectationRevenue Estimate
$2.22 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 56.76% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 28.17%▼ 83.55% |
|---|---|
| Total Invested | $554.36M▼ 66.23% |
| Investors Holding | 57▼ 91.00% |
ESG Score
No data